What Researchers Did
Researchers investigated the early effects of hyperbaric oxygen therapy (HBOT) on inflammation and cell signaling markers in 19 patients with type 1 diabetes and peripheral arterial disease.
What They Found
After 10 sessions of HBOT, where patients inhaled 100% oxygen at 2.4 ATA for one hour, plasma C-reactive protein (CRP) and free fatty acids (FFA) significantly decreased (p < 0.001). Inducible nitric oxide synthase (iNOS) protein expression and serum nitrite/nitrate levels also decreased (p < 0.01), while serum arginase activity increased (p < 0.05). These changes suggest HBOT reduced iNOS activity by affecting specific cell pathways like ERK1/2, Akt, and NFκB.
What This Means for Canadian Patients
These findings suggest that HBOT may help reduce inflammation and modify cell signaling pathways in Canadian patients with type 1 diabetes. This could potentially offer a new approach to managing some diabetes-related complications by influencing how cells respond to stress and inflammation. However, more research is needed to confirm these benefits.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This was a pilot study with a small group of 19 patients, which limits how broadly the findings can be applied.